Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 May 2022 | Story Leonie Bolleurs | Photo Leonie Bolleurs
Astrophysics
The Astrophysics Research Group in the UFS Department of Physics recently collaborated with the Institute of Astrophysics of Andalusia (IAA) in Spain and the University College of Dublin (UCD) in Ireland, to install a robotic telescope at the Boyden Observatory. Pictured here, are from the bottom, Teboho Rakotsoana and Simon Rakotsoana from the UFS; Emilio J Garcia from the Institute of Astrophysics of Andalusia; Prof Pieter Meintjes; and Prof Antonio M Carrillo from UCD.

The Astrophysics Research Group in the Department of Physics at the University of the Free State (UFS) is part of an international collaboration with the Institute of Astrophysics of Andalusia (IAA) in Spain and the University College of Dublin (UCD) in Ireland, which focuses on measuring the brightness of transient sources. Knowledge gained from studying these cosmic X-ray sources, which seem to appear in the sky for a short time before disappearing, will lead to a more complete and better understanding of the universe, believes Prof Pieter Meintjes, Professor of Physics and Head of the Astrophysics Programme in the Department of Physics.

To facilitate these observations, a robotic telescope network has been established, with the Boyden Observatory selected as one of the sites for BOOTES 6 (a Burst Observer and Optical Transient Exploring System).

The UFS and the IAA started working on this project more than two years ago. The foundation and pier were built through a local tender, and in January 2020, part of the dome of the structure housing the telescope arrived by ship. Due to the COVID-19 pandemic there were some delays, resulting in the crew from Spain only arriving in South Africa with the telescope and hardware in November 2021, but having to return to their country without completing the installation. They returned in April, and in early May completed assembling the telescope in collaboration with UFS researchers and technicians.

Robotic telescope opportunity to further own research

The main scientific objective of the robotic telescope is to observe and monitor the optic counterparts of gamma-ray bursts as quickly as possible when detected from space or other ground-based observatories.

Prof Meintjes says they will use the telescope to observe these transient sources that goes into an eruptive phase for a short span of time. “Since BOOTES has an enormously fast slew rate, it can start observations of erupting sources within a few seconds, which allows the Astrophysics Research Group to get data very quickly. This will certainly give us an edge over other international astronomy groups that are also involved in the same type of research,” says Prof Meintjes, the local coordinator of the project who is overseeing the whole operation locally. 

He explains the importance of monitoring these packets of enormous energy. “By observing the optical afterglow of the gamma-ray bursts, we can establish its point of origin in space. Furthermore, the shape of the optical afterglow light curve gives insight into the type of mechanism behind the gamma-ray burst, i.e., whether the burst is produced by a collision between two neutron stars or by the explosion of a hypernova event.” 

The knowledge gained with research made possible by the robotic telescope will lead to a more complete and better understanding of the universe. – Prof Peter Meintjes

The UFS Astrophysics Research Group, with its research focus on high-energy astronomy and the physics behind gamma-ray bursts, has a particular interest in this project. As the local custodians of the project and in terms of a memorandum of understanding, the group is guaranteed a certain amount of telescope time for its own in-house observation programmes.

Project expands UFS’ international research footprint

Besides the opportunity for knowledge exchange, this project establishes Bloemfontein as a region where research of international quality is being done and will help to attract talented learners to the UFS. “The successful operation of the robotic telescope may also draw more international groups to bring robotic telescopes to Boyden, thus expanding our international research footprint,” he adds. 

The fact that the Boyden Observatory is in the Southern Hemisphere and has access to the galactic centre region with its host of very interesting astronomical objects and the Magellanic Clouds, makes it a very attractive site for astronomical research,” says Prof Meintjes. 

(Dr Pat van Heerden from the UFS Department of Physics. Photo: Supplied)

“We also have a number of years of experience in robotic telescopes in the sense that we have been hosting the Watcher telescope, operated by the University College Dublin in Ireland, since 2001. Once mounted in middle May 2022, this will then be Boyden’s second robotic telescope.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept